Funding for Medical Research
and Clinical Trials
and Clinical Trials
Funding Details for Heart
Use the contact information shown for the organization to apply for the funding.
Please notify CenTrial of any offer is incorrect or has expired.
Please notify CenTrial of any offer is incorrect or has expired.
Heart and Lung
The International Society for Heart and Lung Transplantation (ISHLT)
Type of Organization: Foundation
Email Address: information@ishlt.org
Funds Available for Clinical Trials: ✗ Research: ✔
The applicant must have an academic appointment at an accredited institution of higher learning.
An individual may apply for the research grant while still in training. However, they must have been offered and accepted a faculty position that will begin on or before initiation of the grant.
ISHLT Membership
The applicant must be an active member of ISHLT or have submitted a completed membership application by the grant deadline.
Previous ISHLT Funding/Funding from Other Sources
There are no restrictions on past or current funding.
The applicant may be a past or current recipient of an ISHLT Fellowship or Faculty Development research grant.
The applicant may currently hold career development awards, mentoring awards, or other independent research awards.
If the applicant is currently receiving funding for a project similar to the topics described in this RFA, the applicant should explain how the funds of the grant would not overlap with the funds of the other research support.
Miscellaneous
Applicants who have a substantial relationship with CareDx that would present a real or perceived conflict of interest if awarded this grant must first contact ISHLT to declare the conflict before submitting an application.
Other info: Purpose
The purpose of this grant is to support transplantation and immunology research by testing the utility of donor-derived cell-free DNA (dd-cfDNA), gene expression profiling, or the combination thereof for heart or lung transplant recipients.
Research Priorities
This grant will fund research that tests the utility of the combination of donor-derived cell-free DNA (dd- cfDNA) and gene expression profiling (GEP) in heart transplantation, or utility of dd-cfDNA in lung transplantation. The research will focus on how these noninvasive tools improve outcomes for transplant recipients.
Although rates of acute rejection have declined after solid organ transplantation, there is an unmet need to better define the molecular phenotype of rejection and provide non-invasive, precision medicine tools to better detect rejection. The standard-of-care for detecting allograft rejection is pathology-read biopsy, which suffers from sampling error, interobserver variability, and artefacts that result in often subjective and varying diagnoses of allograft rejection. Genomic medicine, including biomarkers such as donor-derived cell-free DNA, may permit non-invasive and earlier detection of allograft injury and rejection, and may allow for quantitative serial monitoring of graft health and response to rejection treatment. Another genomic medicine technique for monitoring allograft function is gene expression profiling (GEP) of peripheral blood. GEP characterizes changes in gene expression (upregulation and downregulation of genes) that identify pathologic states. GEP and dd-cfDNA, separately and in combination, show potential utility for monitoring allograft health and identifying graft injury sooner and more accurately than the standard-of-care. We seek investigators who will test the value of such noninvasive tools for allograft surveillance through improved outcomes, reduction in mortality and morbidity to patients, increased graft survival, improved quality of life and reduced costs to the health system. There is also scope for genomic medicine to guide immunosuppression and rejection treatment. Proposals that aim to determine if these tools can improve outcomes through immunomodulation or guiding rejection treatment are also encouraged.
The International Society for Heart and Lung Transplantation (ISHLT)
Type of Organization: Foundation
Email Address: information@ishlt.org
Funds Available for Clinical Trials: ✗ Research: ✔
Funding Details
Requirements: Academic Appointment and Institutional ResourcesThe applicant must have an academic appointment at an accredited institution of higher learning.
An individual may apply for the research grant while still in training. However, they must have been offered and accepted a faculty position that will begin on or before initiation of the grant.
ISHLT Membership
The applicant must be an active member of ISHLT or have submitted a completed membership application by the grant deadline.
Previous ISHLT Funding/Funding from Other Sources
There are no restrictions on past or current funding.
The applicant may be a past or current recipient of an ISHLT Fellowship or Faculty Development research grant.
The applicant may currently hold career development awards, mentoring awards, or other independent research awards.
If the applicant is currently receiving funding for a project similar to the topics described in this RFA, the applicant should explain how the funds of the grant would not overlap with the funds of the other research support.
Miscellaneous
Applicants who have a substantial relationship with CareDx that would present a real or perceived conflict of interest if awarded this grant must first contact ISHLT to declare the conflict before submitting an application.
Other info: Purpose
The purpose of this grant is to support transplantation and immunology research by testing the utility of donor-derived cell-free DNA (dd-cfDNA), gene expression profiling, or the combination thereof for heart or lung transplant recipients.
Research Priorities
This grant will fund research that tests the utility of the combination of donor-derived cell-free DNA (dd- cfDNA) and gene expression profiling (GEP) in heart transplantation, or utility of dd-cfDNA in lung transplantation. The research will focus on how these noninvasive tools improve outcomes for transplant recipients.
Although rates of acute rejection have declined after solid organ transplantation, there is an unmet need to better define the molecular phenotype of rejection and provide non-invasive, precision medicine tools to better detect rejection. The standard-of-care for detecting allograft rejection is pathology-read biopsy, which suffers from sampling error, interobserver variability, and artefacts that result in often subjective and varying diagnoses of allograft rejection. Genomic medicine, including biomarkers such as donor-derived cell-free DNA, may permit non-invasive and earlier detection of allograft injury and rejection, and may allow for quantitative serial monitoring of graft health and response to rejection treatment. Another genomic medicine technique for monitoring allograft function is gene expression profiling (GEP) of peripheral blood. GEP characterizes changes in gene expression (upregulation and downregulation of genes) that identify pathologic states. GEP and dd-cfDNA, separately and in combination, show potential utility for monitoring allograft health and identifying graft injury sooner and more accurately than the standard-of-care. We seek investigators who will test the value of such noninvasive tools for allograft surveillance through improved outcomes, reduction in mortality and morbidity to patients, increased graft survival, improved quality of life and reduced costs to the health system. There is also scope for genomic medicine to guide immunosuppression and rejection treatment. Proposals that aim to determine if these tools can improve outcomes through immunomodulation or guiding rejection treatment are also encouraged.